Inmune Bio Inc (INMB)

$8.58

+0.11

(+1.3%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $8.31
    $8.72
    $8.58
    downward going graph

    3.16%

    Downside

    Day's Volatility :4.71%

    Upside

    1.61%

    downward going graph
  • $6.50
    $14.74
    $8.58
    downward going graph

    24.24%

    Downside

    52 Weeks Volatility :55.9%

    Upside

    41.79%

    downward going graph

Returns

PeriodInmune Bio IncSector (Health Care)Index (Russel 2000)
3 Months
-24.98%
6.5%
0.0%
6 Months
-29.88%
7.1%
0.0%
1 Year
-0.35%
9.8%
0.0%
3 Years
-47.78%
14.2%
-20.2%

Highlights

Market Capitalization
163.4M
Book Value
$1.57
Earnings Per Share (EPS)
-1.92
Wall Street Target Price
19.67
Profit Margin
0.0%
Operating Margin TTM
-78692.86%
Return On Assets TTM
-35.53%
Return On Equity TTM
-81.82%
Revenue TTM
131.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-63.2%
Gross Profit TTM
374.0K
Diluted Eps TTM
-1.92
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.6
EPS Estimate Next Year
-2.55
EPS Estimate Current Quarter
-0.53
EPS Estimate Next Quarter
-0.63

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Inmune Bio Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 129.25%

Current $8.58
Target $19.67

Technicals Summary

Sell

Neutral

Buy

Inmune Bio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inmune Bio Inc
Inmune Bio Inc
16.19%
-29.88%
-0.35%
-47.78%
-63.13%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inmune Bio Inc
Inmune Bio Inc
NA
NA
NA
-2.6
-0.82
-0.36
NA
1.57
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inmune Bio Inc
Inmune Bio Inc
Buy
$163.4M
-63.13%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Inmune Bio Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 46.0K → 14.0K (in $), with an average decrease of 30.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.40M → -11.02M (in $), with an average decrease of 31.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 62.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 234.3%

Institutional Holdings

  • Vanguard Group Inc

    2.74%

  • BlackRock Inc

    1.21%

  • Mccormack Advisors International

    0.92%

  • Rhenman Partners Asset Management AB

    0.90%

  • Geode Capital Management, LLC

    0.86%

  • Millennium Management LLC

    0.80%

Company Information

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.

Organization
Inmune Bio Inc
Employees
11
CEO
Dr. Raymond Joseph Tesi M.D.
Industry
Medical Specialties

Discover More

FAQs